Resistance against novel anticancer metal compounds: Differences and similarities
- 30 April 2008
- journal article
- review article
- Published by Elsevier BV in Drug Resistance Updates
- Vol. 11 (1-2), 1-16
- https://doi.org/10.1016/j.drup.2008.02.002
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- Current status of excision repair cross complementing-group 1 (ERCC1) in cancerCancer Treatment Reviews, 2007
- Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple MyelomaCancer Cell, 2007
- Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple MyelomaCancer Cell, 2007
- Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24)Biochemical Pharmacology, 2007
- Molecular mechanisms of resistance and toxicity associated with platinating agentsCancer Treatment Reviews, 2007
- Recognition and processing of cisplatin- and oxaliplatin-DNA adductsCritical Reviews in Oncology/Hematology, 2005
- Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinomaEuropean Journal of Cancer, 2004
- Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-AEuropean Journal Of Cancer, 2004
- Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panelBiochemical Pharmacology, 1996
- Anti-leukaemic action of RuCl2(DMSO)4 isomers and prevention of brain involvement on P388 leukaemia and on P388DDP sublineEuropean Journal of Cancer, 1993